Reason: MRNA/VRTX round-tripped hard from a parabolic run (RSI 82 to mid-50s), confirming the prior trim-not-chase call; AMGN/TMO stayed the steadiest large-cap accumulate names for a third scan running.

Tape-read: Biotech gave back its hot pocket. MRNA and VRTX — the two most extreme names in the dataset last read (RSI 81.9/81.6) — both round-tripped: MRNA fell to RSI 54.8 (price -16.5% to $68.27, still +76.7% vs VWAP but down from +114.7%), and VRTX to RSI 53.1 (price -8.3% to $485.39, -9.1% off its 52-week high). The "trim/protect, don't chase" call from last scan paid off directly. AMGN and TMO barely moved — AMGN RSI 58.6, +11.6% vs VWAP; TMO RSI 64.7, +10.9% 30D, +3.2% vs VWAP — both remain the cleanest large-cap accumulate setups for a third scan running. Source: 2026-07-11-biotech-scan + summaries/biotech.json.

• MRNA — PASS (round-tripped): RSI 54.8 (was 81.9), strong-up, -16.5% price this week, still +76.7% vs VWAP (down from +114.7%) — the parabolic move gave back most of its run; the prior trim/protect call played out.
• VRTX — PASS (round-tripped): RSI 53.1 (was 81.6), strong-up, -8.3% price this week, -9.1% off 52wk high — same de-risking as MRNA, no longer near-ATH-extreme.
• AMGN — PROMOTE: RSI 58.6, strong-up, golden cross, +11.6% vs VWAP, barely moved — cleanest large-cap accumulate three scans running.
• TMO — PROMOTE/WATCH: RSI 64.7, up trend (still death-crossed on the shorter trend), +10.9% 30D, +3.2% vs VWAP — steady climber, thesis intact.

Lead pick: AMGN — RSI 58.6, un-extended, three straight scans of clean, low-drama basing. MRNA/VRTX are the reversal story this week: both proved the "don't chase a hot pocket" call correct, round-tripping most of their prior run.